#Gynesonics, a #healthcare startup based in #California, secures $42.5 million. The round, anchored by Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital, bringing the total amount invested since the initial investment in April 2023 to $67.2M. Additional investments came from MVM Partners and other #healthcare investors. The funds will be used by the company to expand both its operations and its clientele. Gynesonics is committed to developing and offering minimally invasive, incision-free, #uterus-preserving #transcervical technologies for medical and diagnostic use. Skip Baldino is the company's president and CEO. The company's main offering, the #Sonata System®, is an FDA-approved medical device utilised for #transcervical treatment of symptomatic uterine fibroids, a condition that affects approximately eighty percent of adult women, and diagnostic #intrauterine imaging. Fibroid removal prior to the Sonata System was restricted to #invasive medical treatments such as #hysterectomy, which entails a higher degree of risk and requires a substantially longer recovery period. With Sonata's cutting-edge technology, fibroids can be removed in about 45 minutes as an #outpatient operation, and most patients can return to their regular activities the following day. The Sonata System bears the CE mark and is authorised for retail sales in the US, the UK, Switzerland, and the EU. Gynesonics, Inc. Endeavour Vision Kaiser Permanente Ventures Runway Growth Capital MVM Partners Skip Baldino #gynesonics #funding #startup
